Auna SA (AUNA) FinancialsAUNAAuna SA

Auna SA (AUNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Healthcare services in Colombia, accounting for 34.4% of total sales, equivalent to PEN 425.74M. Other significant revenue streams include Oncosalud Peru and Healthcare services in Mexico. Understanding this composition is critical for investors evaluating how AUNA navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Auna SA maintains a gross margin of 35.72%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.09%, while the net margin is 2.64%. These profitability ratios, combined with a Return on Equity (ROE) of 0.92%, provide a clear picture of how effectively AUNA converts its operational activities into shareholder value.

In the context of the broader market, AUNA competes directly with industry leaders such as DNA and BDSX. With a market capitalization of $388.06M, it holds a significant position in the sector. When comparing efficiency, AUNA's gross margin of 35.72% stands against DNA's 91.47% and BDSX's 82.06%. Such benchmarking helps identify whether Auna SA is trading at a premium or discount relative to its financial performance.

Auna SA reported a consolidated revenue of S/1,238 million for Q2 2026, reflecting a 9% increase year-over-year. However, adjusted EBITDA decreased by 9%, indicating challenges in maintaining profitability despite revenue growth.